Recent Quotes

No Recent Quote currently available

My Portfolio

My Portfolio Tracker

One of the most important steps you can take today is to set up your portfolio tracker on Zacks.com. Once you do, you'll be notified of major events affecting your stocks and/or funds with daily email alerts. Set yours up today.

Zacks #1 Stocks on the Move 04/15/2014

Company Name Symbol %Change
GENERAL MOLY GMO
10.20%
ENERNOC INC ENOC
8.62%
GENERAL FINA GFN
5.67%
ODYSSEY MARI OMEX
5.50%
QIHOO 360 TE QIHU
4.38%
Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference

Print Share

SALT LAKE CITY, Dec 17, 2012 (GLOBE NEWSWIRE via COMTEX) -- Myriad Genetics, Inc. (Nasdaq:MYGN) announced today that Peter D. Meldrum, President and CEO, is scheduled to present at the 2013 J.P. Morgan Annual Healthcare Conference, at 9:30 a.m. Pacific Time on Monday, January 7, 2013. The conference is being held at the Westin St. Francis in San Francisco, California.

The presentation will be available to interested parties through a live webcast accessible on the investor relations section of Myriad's website at www.myriad.com.

About Myriad Genetics

Myriad Genetics is a leading molecular diagnostic company dedicated to making a difference in patients' lives through the discovery and commercialization of transformative tests to assess a person's risk of developing disease, guide treatment decisions and assess risk of disease progression and recurrence. Myriad's portfolio of molecular diagnostic tests are based on an understanding of the role genes play in human disease and were developed with a commitment to improving an individual's decision making process for monitoring and treating disease. Myriad is focused on strategic directives to introduce new products, including companion diagnostics, as well as expanding internationally. For more information on how Myriad is making a difference, please visit the Company's website: www.myriad.com

Myriad, the Myriad logo, BRACAnalysis, Colaris, Colaris AP, Melaris, TheraGuide, Prezeon, OnDose, Panexia and Prolaris are trademarks or registered trademarks of Myriad Genetics, Inc. in the United States and foreign countries. MYGN-G

CONTACT: Investor Relations
         Jim Evans, Chief Financial Officer
         (801) 584-1143
         investors@myriad.com
         Media Relations
         Stephanie Ashe
         Continuum Health Communications
         sashe@continuumhealthcom.com

http://www.globenewswire.com/newsroom/ti?nf=MTMjMTAwMTU2NTEjMTU0NTk=

(C) Copyright 2012 GlobeNewswire, Inc. All rights reserved.

**********************************************************************

As of Thursday, 12-13-2012 23:59, the latest Comtex SmarTrendA? Alert,
an automated pattern recognition system, indicated a DOWNTREND on
04-20-2012 for JPM @ $43.15.

For more information on SmarTrend, contact your market data
provider or go to www.mysmartrend.com

SmarTrend is a registered trademark of Comtex News Network, Inc.
Copyright A? 2004-2012 Comtex News Network, Inc. All rights reserved.

Free Stock Analysis From Zacks

Includes Zacks Long-Term Recommendation and Target Price

Zacks Research is Reported On:

Zacks Investment Research

is an A+ Rated BBB

Accredited Business.